Skip to main content
Uncategorized

Omnia Molecular closes a funding round of 2.1 million Euros

By 9 de November de 2010November 18th, 2020No Comments
< Back to news
 09.11.2010

Omnia Molecular closes a funding round of 2.1 million Euros

The biotech Omnia Molecular, located at the PCB-Santander Bioincubator of the Barcelona Science Park, has closed a funding round of 2.1 million Euros led by Caixa Capital Risc, the venture capital manager of "la Caixa". Promoting partners (Lluís Ribas, Juan Gargallo and Eugeni Roure) and the new management team, which consists of Raphael Klingmann, who will take on the deputy councilor position, and Dariusch Mani, will also be participating in this round, which is endorsed by the National Company of Innovation (ENISA).

Omnia Molecular is dedicated to the discovery and development of new antibiotic compounds. The company owns a new technology that detects antibiotic activity and the potential toxicity of new compounds, accelerating the discovery and development process of effective and non-toxic compounds. The objective of this new funding round is to finance the development of its most promising compounds and enter the pre-clinical phase with several of these compounds in 2012. The first trials with human beings are slated for 2014. Some of these compounds are expected to be co-developed with partners from the pharmaceutical industry once their efficacy has been proven in animal models.

Since 2008 Omnia Molecular has validated its technology for use in different pathogens, demonstrating its technical feasibility and setting up trials for the research of new drugs. At present, there are three trials optimized to discover potentially therapeutic compounds, and agreements with several companies and institutions to exploit their compound libraries in the research of interesting molecules.